INTRODUCTION.
Cytogenetic studies in acute lymphoblastic leukemia (ALL) reveal a wide variety of translocations involving this disease which can either deregulate an intact gene by disruption or removal and replacement of the adjacent controlling elements, or create a new fusion gene [1] [2] . Chromosome translocation is clearly an important oncogenic step in ALL and structurally altered genes play key roles in cell proliferation, differentiation, apoptosis and gene transcription. Although these molecular abnormalities may serve as diagnostic and prognostic markers, they are detectable at only low rates in specific morphological subtypes of ALL [1] [2] . Furthermore, oncogenes and tumor-suppressor genes that are frequently altered in solid tumors, such as p53 or RAS, are infrequently mutated in ALL 3 . In addition to these genetic changes, epigenetic silencing of tumorrelated genes, due to hypermethylation, has recently emerged as one of the pivotal alterations in cancer development [4] [5] [6] .
In the mammalian genome, methylation takes place only at cytosine bases that are located 5' to guanosine in a CpG dinucleotide [4] [5] [6] . This dinucleotide is actually under-represented in much of the genome, but short regions of 0.5-4 Kb in length, known as CpG islands, are rich in CpG content. Most CpG islands are found in the proximal promoter regions of almost half of the genes in the human genome and are, generally, unmethylated in normal cells. In cancer, however, the hypermethylation of these promoter areas, is the most well-recognized epigenetic change to occur in tumors; it is found in virtually every type of neoplasm and is associated with the inappropriate transcriptional silencing of genes [4] [5] [6] . Thus, aberrant methylation serves as an alternative mechanism of gene inactivation in neoplasia and, surprisingly, such promoter hypermethylation is at least as common as the disruption of classic tumorsuppressor genes in human cancer by mutation or deletion and possibly more so.
In addition, promoter hypermethylation and transcriptional repression of functionally important cancer-related genes may also affect tumor behavior, impacting clinical outcomes. Epigenetic silencing of genes that determine tumor invasiveness, growth patterns and apoptosis, in particular, may dictate tumor recurrence after treatment and impact overall survival. Because each tumor may harbor multiple genes susceptible to promoter hypermethylation, individual tumors would exhibit different frequencies of hypermethylation profile potentially predictive of a patient's clinical outcome [7] [8] .
Although several reports concerning methylation of different genes in ALL have been published, in most cases the methylation status has been investigated for just a single gene or in a small number of patients with short follow-up. We and others have only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From identified several methylated genes in ALL including, CALCA, ER, MDR1, THBS2, MYF3, p15, p16, p73, p57 and CDH1 [9] [10] [11] [12] [13] [14] [15] . Moreover, methylation patterns may have clinical implications in ALL in that CALCA, p15, p57, and p21 methylation were found to be associated with dismal outcome [11] [12] [13] [14] [15] . However, it is unclear whether methylation of these genes are prognostic because of their own regulating functions or whether they reflect a distinct pathway of tumorigenesis in ALL, with distinct expression profiles of genes that could influence prognosis, as a consequence of the methylation of multiple loci simultaneously. To study this issue further, we have examined multiple key cancer genes undergoing epigenetic inactivation in a large set of de novo ALLs with the aim of obtaining a map of this alteration in the disease and its possible correlation with clinical features and outcome of the patients.
MATERIAL AND METHODS:
Patients: We studied 251 consecutive patients (151 male; 100 female) who were diagnosed with de novo ALL between January 1990 and December 2002. The median age at diagnosis in the study population as a whole was 14 years (range, 0.5-82 years). Of these patients, 124 were children (median age, 5 years; range, 0.5-14 years) and 127 presented adult ALL (median age, 29 years; range, 15-82 years).
Informed consent was obtained from the patient or the patient's guardians. Diagnosis was established according to standard morphologic, cytochemical and immunophenotypic criteria. Patients were studied at the time of initial diagnosis; were risk-stratified according to the therapeutic protocol used, which was always based on recognized prognostic features (including cytogenetics); and were entered in ALL protocols of the "Programa para el estudio y tratamiento de las hemopatias malignas" (PETHEMA) Spanish study group. For statistical analyses, children were also grouped according to the National Cancer Institute (NCI) risk-classification criteria Table 1. only. Gene selection: High-molecular weight DNA and total RNA were prepared from mononuclear marrow cells at the time of diagnosis using conventional methods. In all the cases, the diagnostic bone marrow sample contained blast cells in the ratio of at least 70%. We studied 15 genes belonging to all of the molecular pathways involved in cell immortalization and transformation: cell cycle (p15, p16 and p57), cell adherence and metastasis process (CDH1 and CDH13), p53 network (p14 and p73), apoptosis (TMS1, APAF-1 and DAPK), cellular senescence (DKK-3), differentiation regulation (NES-1), ubiquitylation (PARKIN) and main tumor-suppressor genes (LATS-1 and PTEN) ( Table 2 ). Different criteria were used for gene selection. CDH1, p73, p16, p15, p57, NES-1 and DKK-3 were selected because of their frequent methylation in ALL 9-11, 15, 21-22 . CDH13, p14, TMS1, APAF-1, DAPK, PARKIN, LATS-1 and PTEN were studied because they have been found to be methylated in other malignancies, and their abnormal expression could have potentially important roles in ALL [23] [24] [25] [26] [27] [28] [29] [30] .The regions where these genes reside, are not prone to mutations, deletions or rearrangement in the majority of human leukemias, however, microsatellite markers from these regions have shown that most of them are common sites for loss of heterozygocity in ALL 31 .
Each of these genes possesses a CpG island in the 5' region which is normally unmethylated in corresponding normal tissues as expected for a typical CpG island.
We and others have shown, in previous studies for such genes in individual tumor types, that when these CpG islands are hypermethylated in cancer cells, expression of the corresponding gene is silenced and the silencing can be partially relieved by demethylation of the promoter region 9-11, 15, 21-30 . For all these genes, we have analyzed, at least, ten normal marrow and peripheral blood specimens, none of which showed significant methylation. TSG, tumor suppressor gene. For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From reactions have been reported elsewhere 9-11, 15, 21-30 . "Hot start" PCR was performed for 30 cycles consisting of denaturation at 95ºC for 1 min, annealing at 60ºC for 1 min, and extension at 72ºC for 1 min, followed by a final 7-min extension for all primer sets. The products were separated by electrophoresis on 2% agarose gel. Bone marrow DNA from healthy donors was used as negative control for methylation-specific assays. For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From measured from the day that CR was established until either relapse or death without relapse, and it was censored only for patients who were alive without evidence of relapse at the last follow-up. Distributions of OS and DFS curves were estimated by the method of Kaplan and Meier, with 95% confidence intervals calculated by means of Greenwood's formula. Comparisons of OS or DFS between groups were based on the log-rank test. Comparisons adjusted for significant prognostic factors were based on Cox regression models and hazard regression models. All relapse and survival data were updated on December, 2003, and all follow-up data were censored at that point.
Methylation-specific PCR (MSP):

RESULTS:
Frequency of methylation in ALL: Among 251 ALLs, the methylation frequencies (in descending order) were as follows: 57% for NES-1, 40% for LATS-1, 37% for CDH1, 35% for CDH13, 35% for p16, 34% for APAF-1, 33% for DKK-3, 29% for p15, 27% for PARKIN, 20% for PTEN, 18% for p57, 18% for p73, 13% for DAPK, 9% for TMS-1 and 8.5% for p14 (Table 3) . No methylated genes were found in 57 of 251 patients (22.7%) whereas most ALLs [194 (77.3%) of 251] had methylation of at least one gene, ranging from one to ten methylated genes (Table 3) . No case was found to have methylation of more than 10 genes. According to the number of methylated genes observed in each individual sample, 104 patients (41.4%) were included in methylated-group A (1-3 methylated genes) and 90 (35.9%) in methylatedgroup B (more than 3 methylated genes). Significant differences were found between methylation profiles in children and adults. LATS-1 (P=.05), CDH1 (P=.05), p15 (P=.05), p57 (P=.001) and p14 (P=.05) genes were more frequently methylated in adult ALL than in childhood ALL (Table 3) . Moreover, 82.7% of adult ALLs showed methylated genes compared with 71.8% of childhood ALLs (P=.03, Table 3 ). Figure 1 illustrates representative examples of the methylation patterns of the most frequently methylated genes.
By analyzing the methylation status of 15 genes simultaneously, we were able to study correlations between their methylation status. Methylation of DKK-3, NES-1,   PARKIN, LATS-1, PTEN, p73, p16, p14, CDH1 , CDH13, DAPK and p15 genes were significantly associated (Table 4) . By contrast, methylation of TMS1 and p57 showed no significant correlation with each other or with any above-mentioned group of genes. Separate analysis of adult and childhood ALL patients gave the same results as the global series. Table 1 details the relapse history, CR rates and mortality for patients included in the different methylation groups. CR rates of patients in the non-methylated, methylated-A and methylated-B groups were 91%, 93% and 88%, respectively, accounting for 91% of the overall CR rate. This suggests that methylation profile did not correlate with response to remission induction therapy. However, patients in the nonmethylated group had a lower relapse rate than patients in the methylated groups A and B (17% versus 51% and 59%, respectively, P < .0001). Mortality rate was also lower for non-methylated group compared with methylated groups A and B (28% versus 43% and 61%, respectively, P < .001). Similar results were obtained in the separate analyses of children (relapse rate, 14% for non-methylated group versus 35% and 48% for methylated groups A and B, respectively, P = .003; mortality rate, 14% for only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From non-methylated group versus 20% and 37% for methylated groups A and B, respectively, P = .04) and adults (relapse rate, 28% for non-methylated group versus 67% and 68% for methylated groups A and B, respectively, P = .002; mortality rate, 50% for non-methylated group versus 63% and 81% for methylated groups A and B, respectively, P = .02).
We analyzed the DFS among patients who achieved CR according to the methylation profile. Estimated DFS rates at 11 years were 75.5% and 25.6% for nonmethylated and methylated groups (group A, 37.2%; group B, 9.4%), respectively (P < .0001) (Figure 2A ). Among children, the 11-year DFS was 79.7% for non-methylated group and 36.5% for methylated group (group A: 55%; group B: 18.6%; P = .001)( Figure 2B ). Among adult ALL patients, the 11-year DFS was 66.5% for nonmethylated group and 15.6% for methylated group (group A, 20.4%; group B, 7.1%, P = .001)( Figure 2C ). The actuarial OS at 12 years calculated for all leukemic patients was 66.1% for non-methylated patients and 27.4% for methylated patients( group A, 45.5%; group B, 7.8%; P = .0004)( Figure 3A ). Significant differences were observed in the actuarial OS among non-methylated, methylated A and methylated B groups in the separate analyses of children (78.1%, 75.1% and 18.1%, respectively, P = .01; Figure   3B ) and adults (46.6%, 22.1% and 4.2%, respectively, P = .05; Figure 3C ).
A multivariate analysis of potential prognostic factors (including the type of PETHEMA protocol applied) demonstrated that hypermethylation profile was an independent prognostic factor in predicting DFS in the global series (P< .0001) as well as in both childhood (P= .0001) and adult ALLs (P= .006; Table 5 ). Methylation status was also independently associated with OS in the global series (P= .003) and childhood ALL (P= .02; For ) at diagnosis. Among TEL-AML1-positive children (n=44), the 8-year DFS was 87.5% for non-methylated group and 38% for methylated group (P= .04; Figure   4A ). The actuarial OS at 8 years for the same patients was 100% for non-methylated patients and 77.4% for methylated patients (P= .05; Figure 4A ). Among BCR-ABLpositive patients (n=47), the 6-year DFS was 67.3% for non-methylated patients and 4.1% for methylated patients (P= .001; Figure 4B ). Estimated 7-year OS was 59.8% for non-methylated BCR-ABL patients and 0% for methylated patients (P= .02; Figure 4B ).
Among ALL patients with high WBC count at diagnosis (n=73), DFS at 9 years was 58.3% for non-methylated patients and 11.5% for methylated patients (P= .07; Figure   4C ). No significant difference was observed concerning OS in these patients. 
DISCUSSION:
Epigenetic gene silencing is increasingly being recognized as a common way in which cancer cells inactivate cancer-related genes [4] [5] [6] [7] [8] . Attention has focused on the methylation of regions in the genome that might have functional significance resulting from the extinction of gene activity. Whereas most individual cancers have several, perhaps hundred, of methylated genes (a phenomenon termed CpG island methylator phenotype) 35 , the methylation profiles of individual tumor types are characteristics.
However, there is relatively modest information on this profiling in ALL [13] [14] [15] . Our results indicate that methylation of multiple genes is a common phenomenon in ALL and may be the most important way to inactivate cancer-related genes in this disease; 77.3% of cases had at least one gene methylated, whereas 35.9% of cases had 4 or more genes methylated. Significant differences were found in the methylation profiles of childhood and adult ALLs suggesting that methylation status in ALL is age-related. Adult ALL patients showed more frequent methylation of LATS-1, CDH1, p15, p57 and p14 genes and also a higher number of methylated genes simultaneously than childhood ALL patients. It is well known that prognosis of children with ALL is significantly superior to that of adults, even if they are matched for poor prognosis features; our results suggest that this different epigenetic map may have a role in explaining the prognostic differences between both age groups. Furthermore, methylation of several of the genes analyzed here was strongly correlated, suggesting that CpG island methylation is related to specific methylation defects in subsets of ALLs, rather than that methylation of each individual island represents a random event followed by selection for the affected cell.
Our data also show that the methylation in human ALL cells can participate in the inactivation of three key cellular pathways: i) Growth-deregulating events comprising those that target the principal late-G1 cell-cycle checkpoint either directly In view of our results, one hypothesis is that the methylation of cytosine nucleotides in ALL cells can help to inactivate tumor-suppressive apoptotic or growth-arresting responses by deregulation of the Cyclin-dependent kinases that phosphorylate and functionally inactive RB protein (at p15, p16 and p57 level) and either upstream (at p14 or DAPK) or downstream (APAF-1) of p53 and also inactivating p73 which encodes for a protein that is both structurally and functionally homologous to the p53 protein 39 . This implies that in ALL too there is a strong selection for tumor cells to lose critical tumorsuppressor gene functions (not only p53 and RB but also LATS-1 and PTEN), but in this case, indirectly through an alternative epigenetic way.
In this study we have shown that aberrant methylation of CpG islands is quantitatively different in individual tumors within the same tumor type, and this patientspecific methylation profile provides important prognostic information in ALL patients.
The presence in individual tumors of multiple epigenetic events that affect each of the pathways discussed above is a factor of poor prognosis in both childhood and adult ALL. Patients with methylation of four or more genes had a poorer DFS and OS than patients with three or less methylated genes and patients lacking promoter hypermethylation. Multivariate analysis confirmed that methylation profile was associated with a shorter DFS and OS. Moreover, methylation status was able to redefine the prognosis of selected ALL groups with well-established prognostic For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From studies for guiding the selection of therapy and also providing a basis for developing novel therapies, such as demethylation treatment.
In summary, our results indicate that simultaneously aberrant methylation affecting key molecular pathways is a common phenomenon in ALL. The methylation profile seems to be an important factor in predicting the clinical outcome of ALL patients.
